# Docetaxel in Non Small Cell Lung Cancer (NSCLC)

> **NCT00263016** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 50 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00263016
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 50 (ESTIMATED)
- **Why stopped:** Slow recruitment
- **Last updated:** 2008-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00263016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00263016, "Docetaxel in Non Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00263016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*